CARsgen Therapeutics, a biopharmaceutical company listed on the Hong Kong Stock Exchange (HKG: 2171), has announced promising results from two pivotal clinical trials at the 29th European Hematology Association Annual Meeting. The data presented highlights the potential of two CAR-T therapies: Saikaize (zevorcabtagene autoleucel), an autologous BCMA-targeted therapy for multiple myeloma, and the novel candidate CT071, which targets GPRC5D.
Saikaize, under evaluation in the Phase II LUMMICAR-1 study, is intended for patients with recurrent or refractory multiple myeloma who have seen limited success with prior treatments. From December 2020 to March 2022, 102 patients with a median of four prior lines of treatment were administered Saikaize. As of October 25, 2023, the treatment demonstrated an overall response rate of 92.2%. Notably, only 6.9% of patients experienced grade 3 or higher cytokine release syndrome, indicating a favorable safety profile.
The first-in-human study of CT071 has also shown positive results, with an overall response rate of 90% in heavily pre-treated patients with multiple myeloma. The treatment’s safety was deemed controllable, marking a significant step forward in CAR-T cell therapy development.- Flcube.com
